Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant polycystic kidney disease

Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant polycystic kidney disease - GLSG ADPKD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016998

Enrollment

Registered

2020-01-01

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADPKD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients with bilateral renal volume more than or equal to 750 ml. 2. The patients in which the speed of increasing renal volume more than or equal to 5% per year. 3. The patients achieving informed consent to participate in this trial. 4. The patients with liver cysts.

Exclusion criteria

Exclusion criteria: 1. The patient having a history of allergy to Tolvaptan or its analog. 2. The patient cannot feel thirsty or is unable to consume liquid. 3. The patient with hypernatremia. 4. The patient with severe renal function (less than eGFR 15mL/min/1.73m2). 5. The patient with chronic hepatitis or drug-induced liver injury of the history of these disease (except liver cysts). 6. The pregnant woman or the woman who has the possibility of the pregnancy. 7. The patient whom the primary doctor think not appropriate for participating the trial.

Design outcomes

Primary

Measure	Time frame
The comparison of the volume of liver cysts of 12 months (52 weeks) after administration of Tolvaptan to that prior to the treatment	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results